ORPHANET Company Profile

00:58 EDT 19th March 2018 | BioPortfolio



102 rue Didot

News Articles [0 Results]


Drugs and Medications [0 Results]


PubMed Articles [4 Associated PubMed Articles listed on BioPortfolio]

Harmonising phenomics information for a better interoperability in the rare disease field.

HIPBI-RD (Harmonising phenomics information for a better interoperability in the rare disease field) is a three-year project which started in 2016 funded via the E-Rare 3 ERA-NET program. This project...

An overview of the impact of rare disease characteristics on research methodology.

About 30 million individuals in the United States are living with a rare disease, which by definition have a prevalence of 200,000 or fewer cases in the United States ([National Organization for Rare ...

Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency.

Lysosomal acid lipase deficiency is an autosomal recessive metabolic disease with a wide range of severity from Wolman Disease to Cholesterol Ester Storage Disease. Recently enzyme replacement therapy...

Targeted next-generation sequencing analysis in couples at increased risk for autosomal recessive disorders.

Many of the genetic childhood disorders leading to death in the pre- or neonatal period or during early childhood follow autosomal recessive modes of inheritance and bear specific challenges for genet...

Clinical Trials [0 Results]


More Information about "ORPHANET" on BioPortfolio

We have published hundreds of ORPHANET news stories on BioPortfolio along with dozens of ORPHANET Clinical Trials and PubMed Articles about ORPHANET for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ORPHANET Companies in our database. You can also find out about relevant ORPHANET Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record